Heron Therapeutics, Inc. (HRTX) — Analysis Summary
Heron Therapeutics, Inc. (HRTX) has a market cap of $81.37M with year-over-year revenue growth of +7.4%. Net margin stands at -13.0%. The stock trades at a P/E ratio of -2.6.
Key Takeaways
- Revenue changed +7.4% year-over-year
- Net margin of -13.0%
- P/E ratio of -2.6
Compared to other companies in the PHARMACEUTICAL PREPARATIONS sector, HRTX posted revenue growth of +7.4% and trades at a P/E of -2.6.
Heron Therapeutics, Inc. (HRTX)
UPDATED — ET · SOURCE POLYGON
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Interest coverage at -1.1x — earnings do not cover interest payments
D/E at 3.6x — high financial leverage
Net margin at -20.5% — significant losses
Net income fell 53.2% vs the prior period.
Heron Therapeutics Inc is a commercial-stage biotechnology company. The company is focused on improving the lives of patients by developing treatments and commercializing therapeutic solutions to address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
Sector
PHARMACEUTICAL PREPARATIONS
Employees
128
Headquarters
SAN DIEGO, CA
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.